The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid shifting dynamics in the real estate and biotech sectors, major research firms have initiated coverage on Rexford Industrial and Relmada Therapeutics with diverging outlooks. Raymond James initiated coverage on Rexford Industrial Realty (REXR) with an 'Underperform' rating, citing cautious sentiment and insider selling activity. Conversely, H.C. Wainwright launched coverage on Relmada Therapeutics (RLMD) with a 'Buy' rating and a $12 price target, highlighting the potential of its bladder cancer treatment program despite the firm's current lack of profitability.
The bearish stance on Rexford comes as industrial REITs navigate a complex environment of stabilizing occupancy rates; per market data, investor appetite for logistics warehousing has cooled slightly compared to the previous year. For Relmada, the $12 price target represents significant upside potential from current levels, reflecting a broader trend of analyst optimism toward clinical-stage biotech firms with specialized pipelines, according to market data.
Sign in to access this content
Sign InMonitoring price action, REXR stood at $32.47 while RLMD closed at $6.60 (close June 17, 2026). Traders should watch for upcoming US economic catalysts, such as consumer sentiment data, which may impact industrial demand for Rexford, alongside any clinical milestone updates from Relmada that could validate the aggressive price target set by H.C. Wainwright.